Shanghai Jiaolian Drug Research And Development Co., Ltd

This study tests an injection called B001 in 132 people with a severe nerve disease called NMOSD. The goal is to see if it can prevent sudden attacks that cause vision loss, paralysis, or other serious symptoms. Participants will receive either B001 or a placebo, and researchers …

This study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the comb…

This study tests a new drug called B007 in 132 people with pemphigus, a serious blistering skin disease. The goal is to see if B007 can help patients achieve complete remission while using minimal other treatments. Participants receive injections of B007 at high or low doses, and…

This study tests a new drug, B007, against the standard treatment cyclosporine for people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 216 adults with confirmed disease and adequate kidney function will be randomly assigned to receive e…

This study tests a new drug called B007 in 104 people with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either B007 or a placebo as a shot under the skin twice a month. The goal is to see if B007 improves daily activities, like walk…

This early-stage trial is testing a new drug called B007, given as a shot under the skin, for people with primary membranous nephropathy — a kidney disease where the immune system attacks the kidneys. The study will include 52 adults and will focus on safety, how the drug moves t…